



ABN 53 075 582 740

ASX ANNOUNCEMENT
14 OCTOBER 2021

CLOSING DATE FOR NOMINATION OF DIRECTOR

Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (**Bionomics** or **Company**), a clinical-stage biopharmaceutical company, advises that in accordance with ASX Listing Rule 3.13.1, the Company's next Annual General Meeting (**AGM**) will be held on Thursday, 2 December 2021. An election of directors will be held at this AGM pursuant to ASX Listing Rule 14.5. Details of the Director's to be elected will be included in the Notice of AGM.

The closing date for receipt of director nominations for candidates other than those recommended by the Board is Thursday, 21 October 2021. Any nominations must be received in writing no later than 5.00pm (Adelaide time) on Thursday, 21 October 2021 at the Company's Registered Office.

The Company notes that the deadline for nominations for the position of director is separate to voting on director elections. Details of the director's to be elected will be provided in the Company's Notice of AGM in due course.

Released on authority of the Executive Chairman

FOR FURTHER INFORMATION PLEASE CONTACT:

General:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400

CoSec@bionomics.com.au

Investor Relations:

Mr. Connor Bernstein
Vice President, Strategy and Corporate Development
+1 (831) 246-3642

cbernstein@bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au